Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer

Table 2

Serum HA, SHAP-HA complex, MMP-2, MMP-9, TIMP-1, and UTI in 50 endometrial cancer patients and 50 healthy women.

	𝑛	HA; (ng/mL)	SHAP-HA complex; (U/mL)	UTI; (μg/mL)	MMP-2; (ng/mL)	MMP-9; (ng/mL)	TIMP-1; (ng/mL)
Healthy control	50	52.74±23.87	1.884±1.418	1.930±1.47	707.84±124.20	277.76±117.68	154.16±29.37
Endometrial cancer	50	368.23±233.28	3.294±2.209	7.004±15.044	703.94±182.54	736.40±524.24	223.80±100.79
		𝑃<0.0001	𝑃=0.0002	𝑃=0.0197	𝑃=0.9009	𝑃<0.0001	𝑃<0.0001

Values are shown as mean ± SD.